February 19, 2021 Acad, Gov/Utilities Clinical Research/Diagn. Environ, Ag./Food & Bev Life Science Tools

Illumina and the University Hospital of Tübingen Evaluate Potential of Whole Genome Sequencing to Improve Diagnosis of Full Range of Genetic Diseases

TÜBINGEN, Germany–(BUSINESS WIRE)–February 19, 2021 — Illumina, Inc. (Nasdaq: ILMN) today announced an agreement with the Institute of Medical Genetics and Applied Genomics at the University Hospital of Tübingen to assess the value of whole-genome sequencing (WGS) as a first-line diagnostic test for patients with genetic diseases and familial cancer syndromes. Illumina will support the... Read more

February 16, 2021 Acad, Gov/Utilities Lab Top-10 Liq. Handling & Robotics Product Launch

FDA Grants Emergency Use Authorization for New COVID-19, Flu A, Flu B Combo Kit

One multiplex real-time PCR diagnostic kit can simultaneously detect and differentiate SARS-CoV-2, influenza A and influenza B CARLSBAD, Calif., Feb. 16, 2021 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for the Applied Biosystems TaqPath COVID-19, Flu A, Flu B Combo Kit from Thermo Fisher Scientific, the company announced... Read more

February 8, 2021 Acad, Gov/Utilities

FDA grants Breakthrough Device Designation for Roche's Elecsys Growth Differentiation Factor-15 (GDF-15) assay to help identify patients suitable for innovative treatment addressing unintentional weight loss in cancer patients

FDA BDD acknowledges the importance of GDF-15 testing in identifying eligible cachexic patients with solid tumours to be treated with Pfizer’s investigational drug PF-06946860 Unintentional weight loss (cachexia) is a highly prevalent complication of cancer, affecting more than half of all cancer patients worldwide, potentially leading to significant functional impairment and increased risk of death... Read more

January 28, 2021 Acad, Gov/Utilities Environ, Ag./Food & Bev Life Science Tools Liq. Handling & Robotics

QIAGEN adds dPCR platform QIAcuity to growing portfolio of COVID-19 testing solutions for wastewater and mutation testing

Germantown, Maryland, and Hilden, Germany, January 28, 2021 – QIAGEN today announced the addition of kits for wastewater testing to its growing portfolio of COVID-19 products. The use of dPCR in the worldwide surveillance of COVID-19 is an additional step towards making digital PCR (dPCR) an affordable and standard instrument for a host of applications... Read more

January 25, 2021 Acad, Gov/Utilities Licensing, IP, and Legal M&A, Partnerships Product Launch

Roche renews partnership with Sysmex to deliver haematology testing solutions

This successful long-running partnership continues to evolve and bring haematology testing innovations to laboratories, globally The new agreement aims to utilise the IT systems to lead to improved clinical decision making and customer experience Blood disorders have a high impact, not only for patients but for society as a whole, accounting for a third of... Read more

January 19, 2021 Acad, Gov/Utilities Atomic Spectroscopy Lab Top-10 M&A, Partnerships Microscopy

Shimadzu signs a collaboration agreement with TOTAL, a major Energy player and two European universities.Toward the Development of an Innovative “Oxygenated compound analysis system” for Biofuel Research

Shimadzu signs a collaboration agreement with TOTAL, a major Energy player and two European universities.Toward the Development of an Innovative “Oxygenated compound analysis system” for Biofuel Research Read more

January 12, 2021 Acad, Gov/Utilities M&A, Partnerships

Roche confirms US government agreement to purchase additional doses of Regeneron’s casirivimab and imdevimab

Basel, 12 January 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed that the U.S. Department of Health and Human Services (HHS) and the Department of Defense (DOD) will purchase additional supply of Regeneron’s casirivimab and imdevimab antibody cocktail for use in non-hospitalised COVID-19 patients as part of Operation Warp Speed. The US government... Read more

January 5, 2021 Acad, Gov/Utilities

Roche’s novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designation in combination with Tecentriq for PD-L1-high non-small cell lung cancer

Basel, 5 January 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that tiragolumab, a novel cancer immunotherapy designed to bind to TIGIT, has been granted Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration (FDA), in combination with Tecentriq® (atezolizumab) for the first-line treatment of people with metastatic non-small cell lung... Read more